Navigation Links
BioMS Medical to present at Alberta Economic Forum in Geneva
Date:4/29/2009

stone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 RXi ... company focused on discovering and developing innovative therapies ... today announced that it has commenced a public offering ... purchase shares of its common stock and overallotment ... stock. The shares of common stock, warrants and ...
(Date:5/27/2015)... VANCOUVER , May 27, 2015 /CNW/ - CQDM, ... award close to $8.5M to six (6) multi-disciplinary and ... in neuroscience within their Focus on Brain strategic initiative. ... research entities involved as in-kind contributions. This exciting announcement ... Canadian Association for Neuroscience in the presence of Inez ...
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... The Medical Innovation Impact Index (MI3), ... on medical innovation, has been developed at the ... Dickinson University’s ( FDU ) Rothman Institute of Innovation ... to new FDA (Food & Drug Administration) draft guidance ... of certain medical devices. , “The main impediment ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2
... LAFAYETTE, Ind. - Researchers are developing a new ... for advanced optical technologies, including ultrapowerful microscopes and ... cloak. The new materials could make possible ... an assistant professor of electrical and computer engineering ...
... forces between atoms and surfaces with unprecedented precision, University ... our understanding of the structure of atoms and improve ... Physical Review Letters . Van der Waals ... they are among the weakest known chemical interactions, so ...
... MINNEAPOLIS, Jan. 25, 2011 Thomas, McNerney & Partners, ... in life science and medical technology companies, today announced ... Schiess to Vice President. "These promotions are ... have made as members of the Thomas, McNerney investment ...
Cached Biology Technology:New materials may bring advanced optical technologies, cloaking 2Physicists take new look at the atom 2Physicists take new look at the atom 3Physicists take new look at the atom 4Thomas, McNerney & Partners Promotes Two Members of its Investment Team 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... in China have an increased risk of schizophrenia, consistent ... deficiency and schizophrenia, according to a study in the ... violence and human rights. , Schizophrenia is a common ... hallucinations, and delusions, as well a as deterioration of ...
... scientists replace pricey solvents with cheap processing fluidsIn ... fluorescent quantum dots, scientists at Rice University have ... solvents used in quantum dot synthesis with cheaper ... , Rice's study, which was conducted under the ...
... conducted by a biologist at the University of California, San ... Animal Behaviour found that females of the species Uca crenulata ... their burrows before finally deciding on a mate. , “As ... sampling nearly as many candidates as the California fiddler crab,?said ...
Cached Biology News:Prenatal exposure to famine increases risk of schizophrenia 2The right drug at the right time 2The right drug at the right time 3Biologist Discovers What May Be World’s ‘Pickiest?Mates 2Biologist Discovers What May Be World’s ‘Pickiest?Mates 3
OSCP Antibody...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... polyclonal to Taura Syndrome Virus ... for all tested applications). ... peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN LFEVQDQALI ... to N terminal amino acids ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: